Telix Pharmaceuticals Limited TLX

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $803.79M · Filed Feb 20, 2026

Telix Pharmaceuticals Limited (TLX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $803.8 million and a net loss of $7.1 million. Free cash flow was -$43.0 million. As of Dec 31, 2025 it held $141.9 million in cash and investments and $480.2 million in total debt.

Revenue
$803.79M
Net income
$-7.12M
Operating cash flow
$-17.29M
Free cash flow
$-42.98M
EPS
$-0.02
Dividend per share
None
Shares outstanding
338.78M
+1.2% vs prior year
Net cash
$-338.35M
FY 2025
Operating margin
3.7%
FY 2025

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TLX (Nasdaq), TLPPF (OTC)
Fiscal year ends
December 31
Incorporated in
Australia
Headquarters
North Melbourne, Australia
SEC filer status
Large accelerated filer
SEC CIK
2007191

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$803.8M
Operating income
$29.8M
Net income
-$7.1M
Diluted EPS
-$0.02
Operating cash flow
-$17.3M
Free cash flow
-$43.0M
Total assets
$1.2B
Total liabilities
$748.6M
Stockholders' equity
$415.4M
Cash and investments
$141.9M
Total debt
$480.2M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 29, 2026 Oct 29, 2026
6-K Current report (foreign issuer) Oct 21, 2026 Oct 21, 2026
6-K Current report (foreign issuer) Sep 30, 2026 Sep 30, 2026
6-K Current report (foreign issuer) Sep 21, 2026 Sep 21, 2026
6-K Current report (foreign issuer) Sep 14, 2026 Sep 14, 2026
6-K Current report (foreign issuer) Sep 2, 2026 Sep 2, 2026

All 109 Telix Pharmaceuticals Limited SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.